The Oct. 2-3 hybrid workshop will bridge the gap between critical stakeholders to pinpoint today’s challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
AcCELLerate Forum The Oct. 2-3 hybrid workshop will bridge the gap between critical stakeholders to pinpoint today’s challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
MILWAUKEE, September 21, 2023 (Newswire.com)
– – AcCELLerate Forum, a partnership between Center for International Blood and Marrow Transplant Research (CIBMTR), the American Society for Transplantation and Cellular Therapy (ASTCT), and the National Marrow Donor Program (NMDP)/Be The Match, will bring key stakeholders together to identify ongoing needs and opportunities in cell and gene therapy for advocacy, measurement of value, impact, and sustainability. The Oct. 2-3, workshop at the Sheraton Pentagon City Hotel in Arlington, VA, and online will bring together providers, payers, government agencies, and industry members to define essential factors needed to create a sustainable cell and gene therapy ecosystem.
“CIBMTR is proud to co-sponsor this important forum that interests all key stakeholders across the ecosystem,” said Marcelo Pasquini, MD, MS, Senior Scientific Director, CIBMTR MCW. “Our established relationships with a global network of treatment centers and cell and gene therapy developers uniquely position CIBMTR to bring these experts together to identify the needs and opportunities to adapt to this rapidly evolving field.”
CIBMTR will join industry leaders, treatment-center partners, regulators, and other professionals to discuss the regulatory landscape for the approval of new products. The participants will focus on the perspectives of the payer and regulators, data acquisition and analysis, and center perspectives in defining outcomes for CAR-T cells. They will also discuss logistics for CAR-T, safety and toxicity, and the future directions and competing therapies. The forum will also include breakout sessions on the logistics of cell therapy delivery, efficacy, treatment decisions and sequencing, and manufacturing and logistics standardization in a moderator-led roundtable with attendee participation. Visit the event website to register.
Eligible members of the media are invited to attend AcCELLerate Forum in-person or online at no cost. Please contact Jennifer Kasowicz ([email protected]), Director of Marketing at ASTCT, at (312) 673-4970, to verify eligibility and receive the passcode.
About CIBMTR The Center for International Blood and Marrow Transplant Research (CIBMTR) is a nonprofit research collaboration between the NMDP/Be The Match, in Minneapolis, and the Medical College of Wisconsin, in Milwaukee. CIBMTR collaborates with the global scientific community to increase survival and enrich the quality of life for patients. CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of centers, and a unique database of long-term clinical data for more than 635,000 people who have received hematopoietic cell transplantation and other cellular therapies. Learn more at cibmtr.org.
About ASTCT
The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. For more information about ASTCT, visit www.astct.org and follow us on Twitter, @ASTCT.
About NMDP/Be The Match
The National Marrow Donor Program (NMDP)/Be The Match is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies.
Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran
Total venture funding tops $50M to date
…
HealthAxis, a prominent provider of core administrative processing solutions and BPaaS capabilities to healthcare payers, risk-bearing providers, and third-party administrators, announced it has been Certified™ by Grea…
Leading consultancy for emergency department and trauma center optimization brings its experience and expertise to the foremost conference for emergency department nurses.
The health IT vendor partnership extends Interlace Health’s forms automation and electronic signature capture capabilities to MEDITECH Expanse EHR customers
MEDITECH Alliance Interlace Health is a MEDITECH Alliance Innovator Partner
ST. LOUIS, September 20, 2023 (Newswire.com)
– As a member of the MEDITECH Alliance Innovator Program, Interlace Health delivers proven, successful, and interoperable forms automation, check printing, and eSignature solutions to health systems using MEDITECH Expanse.
Interlace Health works in conjunction with MEDITECH Expanse to enable paperless consenting. Providers can easily and efficiently collect eSignatures from patients and witnesses at the bedside, during clinic visits, and at registration. MEDITECH customers have transformed their eConsent, Patient Intake, Check Printing, and Forms-on-Demand processes with Interlace Health, in theacute, ambulatory, and post-acute care settings.
“We are happy to welcome Interlace to the Alliance,”said James Merlin, Chief Business Development Officer at MEDITECH. “We look forward to customers realizing the benefits of a standardized approach to delivering forms automation, check printing, and eSignature solutions through our partnership.”
MEDITECH Alliance is an ecosystem of healthcare technology companies that effectively collaborate with MEDITECH and complement, enhance, or extend MEDITECH Expanse. The MEDITECH Alliance Innovator Program is an invitation-only program consisting of MEDITECH partners with validated solution integration for specific use cases within Expanse. Innovator solutions are certified with MEDITECH’s technical and application teams. As a result, these solutions will be more deeply integrated in the MEDITECH EHR, with accelerated, seamless deployment based on standardized best practices and shared implementation guides.
As an Innovator, Interlace Health provides leading eForm, check printing, and eSignature solutions to MEDITECH Expanse customers.
“Our partnership and deep integration capabilities with MEDITECH have always been a key component to our success, as well as that of our shared 400+ hospital clients. As an Innovator in the MEDITECH Alliance, we look forward to helping MEDITECH Expanse organizations eliminate remaining paper processes to further drive cost and time savings, improve experiences, and ensure compliance,” said Allison Reichenbach, President at Interlace Health.
Interlace Health looks forward to presenting at MEDITECH LIVE September 20-22, in Foxborough, MA. Learn more about connecting with Interlace Health at MEDITECH LIVE: https://interlacehealth.com/meditech-live-2023/
About Interlace Health
Interlace Health (the next generation of FormFast) delivers forms automation and eSignature solutions that are more scalable and cost-effective than your EHR. For more than 30 years, Interlace Health has pioneered eForms, eSignature, and workflow technology.
By enabling seamless data capture and information exchange among providers, staff, and patients, Interlace Health solves many of healthcare’s central challenges through process transformation. The result for its clients is reduced costs, increased collections, uplifted patient experiences, improved operational efficiency, and enhanced support of an organization’s integration strategy. Interlace Health’s platform enables several solutions that are accessible by clinicians and patients inside and outside the walls of the healthcare system. These include Forms on Demand, Patient Intake, and eConsent. To learn more, visit www.interlacehealth.com.
GUAYNABO, Puerto Rico, September 20, 2023 (Newswire.com)
– Professional Hospital Guaynabo (PHG) issued the following statement in light of the recent ruling by Judge Alfonso Martínez Piovanetti of the Court of First Instance of Puerto Rico, ordering MSO of Puerto Rico, a subsidiary of Elevance Health, to uphold its Hospital Service Agreement (HSA) with PHG throughout the ongoing arbitration process.
“The Court’s decision to uphold the existing partnership between Professional Hospital Guaynabo and MSO of Puerto Rico not only guarantees that our patients will continue to benefit from world-class medical care provided by trusted physicians but also ensures network adequacy and compliance with CMS standards,” stated Administrator Giancarlo Valentín, PhD, MHSA.
Background:
PHG, situated in the Municipality of Guaynabo, serves as the municipality’s sole general hospital, catering to the needs of over 89,000 residents. Providing round-the-clock emergency room services, PHG annually serves 33,000 patients. The hospital achieved Hero Hospital status during both the COVID-19 pandemic and Hurricane Maria, known for its medical expertise in vascular diseases and the performance of cutting-edge surgeries, making it a healthcare cornerstone in Puerto Rico.